Abstract
Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.
Keywords:
CTLA-4; Immune-checkpoint; Immunotherapy; Mesothelioma; PD-1; PD-L1.
Copyright © 2017 Elsevier Ltd. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Humans
-
Immunotherapy / methods*
-
Lung Neoplasms / immunology*
-
Lung Neoplasms / therapy*
-
Mesothelioma / immunology*
-
Mesothelioma / therapy*
-
Mesothelioma, Malignant
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
Substances
-
Antibodies, Monoclonal
-
B7-H1 Antigen
-
CD274 protein, human
-
CTLA-4 Antigen
-
Programmed Cell Death 1 Receptor